RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board
October 14 2020 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced the addition of preeminent
oncology thought leaders, Lisa Butterfield, Ph.D. and Lawrence
Fong, M.D., to its Scientific Advisory Board.
“It’s a very exciting time in the field of immuno-oncology, with
deeper knowledge of biological functions elucidating new ways to
treat disease effectively,” commented Dr. Butterfield. “RAPT’s
comprehensive approach to clinical development employing biomarkers
to identify patients most likely to respond to therapy offers hope
for even the most devastating cancers.”
Dr. Butterfield is the Vice President of Research and
Development at the Parker Institute for Cancer Immunotherapy and an
Adjunct Professor of Microbiology and Immunology at the University
of California, San Francisco. Her research focuses on the
development of advanced cellular therapies and cancer vaccines. She
investigates immunotherapy for hepatocellular cancer and melanoma,
involving peptides, dendritic cells and adenoviruses as well as
effector responses to tumor antigens. Previously, she served as
Professor of Medicine, Surgery, Immunology and Clinical and
Translational Science at the University of Pittsburgh and Director
of the Hillman Cancer Center Immunologic Monitoring and Cellular
Products Laboratory. She was a member of the SITC Executive
Committee for 12 years, serving as President from 2017-2018. For
more than a decade, Dr. Butterfield led the Immunology Reference
Lab for ECOG-ACRIN NCI cooperative group. Dr. Butterfield received
her Ph.D. in Biology from UCLA and completed her postdoctoral
fellowship in Cellular Immunology and Cancer Gene Therapy at UCLA.
She has published more than 170 peer-reviewed manuscripts, reviews
and book chapters.
“RAPT has uniquely tapped into the crossroad within immunology
that impacts both allergy and cancer mechanisms,” said Dr. Fong. “I
look forward to contributing to their research and development
progress and advancing their pipeline of oral small molecules that
offer promise to patients around the globe.”
Lawrence Fong, M.D., is an Efim Guzik Distinguished
Professor in the Division of Hematology/Oncology at
the University of California, San Francisco (UCSF). He
focuses on developing immunotherapies for different cancers
including prostate, kidney, bladder, melanoma, and GI cancers. As a
physician-scientist, Dr. Fong also leads a translational
immunotherapy laboratory. He has been involved in both preclinical
and clinical studies for many cutting-edge immunotherapies. He
directs the Cancer Immunotherapy Program in the UCSF Helen Diller
Family Comprehensive Cancer Center. Dr. Fong obtained his M.D.
at Stanford University, completed internal medicine training
at the University of Washington. He served on the program
committees and editorial boards for the American Society of
Clinical Oncology (ASCO) and the American Association of Cancer
Research (AACR). He is co-director of the Parker Institute for
Cancer Immunotherapy at UCSF and is the site primary investigator
for the NCI-sponsored Cancer Immunotherapy Trials Network
(CITN).
“We are delighted to welcome two world-renowned immunotherapy
leaders to our Scientific Advisory Board,” said Dirk Brockstedt,
Ph.D., Chief Scientific Officer of RAPT Therapeutics. “Lisa brings
incredible expertise in the development of cutting-edge cellular
therapies as well as insight from serving in a leadership role for
two organizations dedicated to developing effective therapies for
cancer patients. Larry’s experience conducting a wide range of
clinical and preclinical trials across varied cancers will provide
integral guidance as we advance FLX475 through clinical development
and complete IND-enabling studies for our pipeline programs.”
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including hematopoietic progenitor kinase 1 (HPK1) and
general control nonderepressible 2 (GCN2), that are in the
discovery stage of development.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or
achievements to be materially different from any future
performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements about clinical development progress and the
timing of results from clinical trials of FLX475 and RPT193.
Detailed information regarding risk factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in RAPT’s Form
10-Q filed with the Securities and Exchange Commission on August
13, 2020 and subsequent filings made by RAPT with the Securities
and Exchange Commission. These forward-looking statements speak
only as of the date hereof. RAPT disclaims any obligation to update
these forward-looking statements.
RAPT Media Contact:Angela
Bittingmedia@rapt.com(925) 202-6211
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024